Biomarkers /
IGK
Overview
Immunoglobulin kappa locus (IGK) is a gene that encodes a protein with unknown function. It is not clear whether IGK mutations have been observed in human cancers.
IGK is altered in 0.18% of all cancers with breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, diffuse large B-cell lymphoma, not otherwise specified, bladder urothelial carcinoma, and Burkitt lymphoma having the greatest prevalence of alterations [3].
The most common alterations in IGK are IGK-MYC Fusion (0.18%) and IGK-BCL2 Fusion (0.04%) [3].
Clinical Trials
Significance of IGK in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.